Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 9/2016

Open Access 01-09-2016 | Original Article

Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016

Authors: Andrew J. Ullmann, Martin Schmidt-Hieber, Hartmut Bertz, Werner J. Heinz, Michael Kiehl, William Krüger, Sabine Mousset, Stefan Neuburger, Silke Neumann, Olaf Penack, Gerda Silling, Jörg Janne Vehreschild, Hermann Einsele, Georg Maschmeyer, on behalf of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation)

Published in: Annals of Hematology | Issue 9/2016

Login to get access

Abstract

Infectious complications after allogeneic haematopoietic stem cell transplantation (allo-HCT) remain a clinical challenge. This is a guideline provided by the AGIHO (Infectious Diseases Working Group) of the DGHO (German Society for Hematology and Medical Oncology). A core group of experts prepared a preliminary guideline, which was discussed, reviewed, and approved by the entire working group. The guideline provides clinical recommendations for the preventive management including prophylactic treatment of viral, bacterial, parasitic, and fungal diseases. The guideline focuses on antimicrobial agents but includes recommendations on the use of vaccinations. This is the updated version of the AGHIO guideline in the field of allogeneic haematopoietic stem cell transplantation utilizing methods according to evidence-based medicine criteria.
Literature
1.
Tabbara IA et al (2002) Allogeneic hematopoietic stem cell transplantation: complications and results. Arch Intern Med 162(14):1558–1566PubMedCrossRef
2.
Hiemenz JW (2009) Management of infections complicating allogeneic hematopoietic stem cell transplantation. Semin Hematol 46(3):289–312PubMedCrossRef
3.
Einsele H et al (2003) Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82(Suppl 2):S175–S185PubMedCrossRef
4.
Ullmann AJ et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clin Microbiol Infect 18(Suppl 7):1–8
5.
Cornet M et al (1999) Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol 20(7):508–513PubMedCrossRef
6.
Eckmanns T, Ruden H, Gastmeier P (2006) The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review. J Infect Dis 193(10):1408–1418PubMedCrossRef
7.
Oren I et al (2001) Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 66(4):257–262PubMedCrossRef
8.
Kruger WH et al (2003) Effective protection of allogeneic stem cell recipients against Aspergillosis by HEPA air filtration during a period of construction—a prospective survey. J Hematother Stem Cell Res 12(3):301–307PubMedCrossRef
9.
Vokurka S et al (2014) The availability of HEPA-filtered rooms and the incidence of pneumonia in patients after haematopoietic stem cell transplantation (HSCT): results from a prospective, multicentre, eastern European study. J Clin Nurs 23(11–12):1648–1652PubMedCrossRef
10.
Humphreys H (2004) Positive-pressure isolation and the prevention of invasive aspergillosis. What is the evidence? J Hosp Infect 56(2):93–100, quiz 163PubMedCrossRef
11.
Hayes-Lattin B, Leis JF, Maziarz RT (2005) Isolation in the allogeneic transplant environment: how protective is it? Bone Marrow Transplant 36(5):373–381PubMedCrossRef
12.
McCann S et al (2004) Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant 33(5):519–529PubMedCrossRef
13.
Harrington RD et al (1992) An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 165(6):987–993PubMedCrossRef
14.
Whimbey E et al (1995) Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 16(3):393–399PubMed
15.
Taylor GS, Vipond IB, Caul EO (2001) Molecular epidemiology of outbreak of respiratory syncytial virus within bone marrow transplantation unit. J Clin Microbiol 39(2):801–803PubMedPubMedCentralCrossRef
16.
McWilliam Leitch EC et al (2001) Dietary effects on the microbiological safety of food. Proc Nutr Soc 60(2):247–255PubMedCrossRef
17.
18.
Allegranzi B, Pittet D (2009) Role of hand hygiene in healthcare-associated infection prevention. J Hosp Infect 73(4):305–315PubMedCrossRef
19.
CE1-7 (2000) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 49(RR-10)1–125
20.
Daeschlein G et al (2007) Hygienic safety of reusable tap water filters (Germlyser) with an operating time of 4 or 8 weeks in a haematological oncology transplantation unit. BMC Infect Dis 7:45PubMedPubMedCentralCrossRef
21.
Zhou ZY et al (2014) Removal of waterborne pathogens from liver transplant unit water taps in prevention of healthcare-associated infections: a proposal for a cost-effective, proactive infection control strategy. Clin Microbiol Infect 20(4):310–314PubMedCrossRef
22.
Cervia JS et al (2010) Point-of-use water filtration reduces healthcare-associated infections in bone marrow transplant recipients. Transpl Infect Dis 12(3):238–241PubMedCrossRef
23.
Kelsey SM, Newland AC (1989) Cytomegalovirus seroconversion in patients receiving intensive induction therapy prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 4(5):543–546PubMed
24.
Hamadani M et al (2010) How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant 45(8):1259–1268PubMedCrossRef
25.
Schmidt-Hieber M et al (2013) CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 122(19):3359–3364PubMedCrossRef
26.
Stewart JA et al (1995) Herpesvirus infections in persons infected with human immunodeficiency virus. Clin Infect Dis 21(Suppl 1):S114–S120PubMedCrossRef
27.
Liang R, Lau GK, Kwong YL (1999) Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 17(1):394–398PubMed
28.
Hammond SP et al (2009) Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(9):1049–1059PubMedCrossRef
29.
Liang R (2009) How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113(14):3147–3153PubMedCrossRef
30.
Knoll A et al (2004) Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 33(9):925–929PubMedCrossRef
31.
Mikulska M et al (2014) Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin Microbiol Infect 20(10):O694–O701PubMedCrossRef
32.
Pompili M et al (2015) Prospective study of hepatitis B virus reactivation in patients with hematological malignancies. Ann Hepatol 14(2):168–174PubMed
33.
Takahata M et al. (2014) Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transpl Infect Dis 16(5):797–801
34.
Peffault de Latour R et al (2008) Allogeneic hematopoietic cell transplant in HCV-infected patients. J Hepatol 48(6):1008–1017PubMedCrossRef
35.
de Latour Peffault R (2004) Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 103(5):1618–1624CrossRef
36.
Locasciulli A et al (1989) Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation 48(1):68–72PubMedCrossRef
37.
Lee JH et al (2005) Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 84(5):321–330PubMedCrossRef
38.
van der Eijk AA et al (2014) Hepatitis E virus infection in hematopoietic stem cell transplant recipients. Curr Opin Infect Dis 27(4):309–315PubMedCrossRef
39.
Versluis J et al (2013) Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood 122(6):1079–1086PubMedCrossRef
40.
le Coutre P et al (2009) Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut 58(5):699–702PubMedCrossRef
41.
Bettinger D et al. (2014) Chronic hepatitis E virus infection following allogeneic hematopoietic stem cell transplantation: an important differential diagnosis for graft versus host disease. Ann Hematol 94(2):359–360
42.
Hutter G, Zaia JA (2011) Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol 163(3):284–295PubMedPubMedCentralCrossRef
43.
Hutter G et al (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360(7):692–698PubMedCrossRef
44.
Hutter G (2014) More on shift of HIV tropism in stem-cell transplantation with CCR5 delta32/delta32 mutation. N Engl J Med 371(25):2437–2438PubMedCrossRef
45.
Henrich TJ et al (2013) Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 207(11):1694–1702PubMedPubMedCentralCrossRef
46.
Au WY, Lie AK, Cheng VC (2005) VDRL screening and haemopoietic stem cell transplantation. Bone Marrow Transplant 35(10):1027–1028PubMedCrossRef
47.
Martino R et al (2005) Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation. Clin Infect Dis 40(1):67–78PubMedCrossRef
48.
Fricker-Hidalgo H et al (2009) Diagnosis of toxoplasmosis after allogeneic stem cell transplantation: results of DNA detection and serological techniques. Clin Infect Dis 48(2):e9–e15PubMedCrossRef
49.
Lee YM et al (2014) A prospective longitudinal study evaluating the usefulness of the interferon-gamma releasing assay for predicting active tuberculosis in allogeneic hematopoietic stem cell transplant recipients. J Infect 69(2):165–173PubMedCrossRef
50.
Menzies D, Pai M, Comstock G (2007) Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 146(5):340–354PubMedCrossRef
51.
Moon SM et al (2013) Comparison of the QuantiFERON-TB gold in-tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation. Transpl Infect Dis 15(1):104–109PubMedCrossRef
52.
Biehl LM et al (2014) Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients—review of the literature from a clinical perspective. Crit Rev Microbiol 42(1):1–16
53.
Liss BJ et al (2012) Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 40(6):613–619PubMedCrossRef
54.
Zirakzadeh A et al (2008) Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 41(4):385–392PubMedCrossRef
55.
Dubberke ER et al (2006) Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant 38(12):813–819PubMedCrossRef
56.
Thouverez M, Talon D, Bertrand X (2004) Control of Enterobacteriaceae producing extended-spectrum beta-lactamase in intensive care units: rectal screening may not be needed in non-epidemic situations. Infect Control Hosp Epidemiol 25(10):838–841PubMedCrossRef
57.
Blot S et al (2005) Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in an intensive care unit. Infect Control Hosp Epidemiol 26(6):575–579PubMedCrossRef
58.
Frere P et al (2004) Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures. Bone Marrow Transplant 33(7):745–749PubMedCrossRef
59.
Mikulska M (2015) How to manage infections caused by antibiotic resistant gram-negative bacteria - EBMT Educational Meeting from the severe aplastic anaemia and infectious diseases working parties, Naples, Italy, 2014. Curr Drug Targets
60.
Mikulska M, Del Bono V, Viscoli C (2014) Bacterial infections in hematopoietic stem cell transplantation recipients. Curr Opin Hematol 21(6):451–458PubMedCrossRef
61.
Hammond SP, Baden LR (2007) Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia. Curr Hematol Malig Rep 2(2):97–103PubMedCrossRef
62.
Bucaneve G et al (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353(10):977–987PubMedCrossRef
63.
Gafter-Gvili A et al (2012) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 1:CD004386PubMedPubMedCentral
64.
Cullen M et al (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353(10):988–998PubMedCrossRef
65.
Leibovici L et al (2006) Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 107(8):1743–1751PubMedCrossRef
66.
Cruciani M et al (2003) Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 21(22):4127–4137PubMedCrossRef
67.
Kimura S et al (2014) Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. J Infect 69(1):13–25PubMedCrossRef
68.
Roy V, Ochs L, Weisdorf D (1997) Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis. Leuk Lymphoma 26(1–2):1–15PubMedCrossRef
69.
Ochs L et al (1995) Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood 86(10):3979–3986PubMed
70.
Kulkarni S et al (2000) Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 95(12):3683–3686PubMed
71.
Mitsui H et al (2003) Analysis of sepsis in allogeneic bone marrow transplant recipients: a single-center study. J Infect Chemother 9(3):238–242PubMedCrossRef
72.
Taur Y et al (2014) The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 124(7):1174–1182PubMedPubMedCentralCrossRef
73.
Taur Y et al (2012) Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 55(7):905–914PubMedPubMedCentralCrossRef
74.
Shono Y et al (2016) Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med 8(339):339ra71PubMedCrossRef
75.
De Castro N et al (2005) Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 36(10):879–883PubMedCrossRef
76.
Tuan IZ, Dennison D, Weisdorf DJ (1992) Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 10(3):267–272PubMed
77.
Williams KM et al (2016) The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. Bone Marrow Transplant 51(4):573–580PubMedPubMedCentralCrossRef
78.
Schneider MM et al (1999) Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 353(9148):201–203PubMedCrossRef
79.
Hughes WT et al (1987) Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 316(26):1627–1632PubMedCrossRef
80.
Hughes WT et al (1977) Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 297(26):1419–1426PubMedCrossRef
81.
Stein DS et al (1991) Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 35(9):1705–1709PubMedPubMedCentralCrossRef
82.
Stern A et al (2014) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 10:CD005590PubMed
83.
Lyytikainen O et al (1996) Late onset Pneumocystis carinii pneumonia following allogeneic bone marrow transplantation. Bone Marrow Transplant 17(6):1057–1059PubMed
84.
Vasconcelles MJ et al (2000) Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant 6(1):35–43CrossRef
85.
Green H et al (2007) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 3:CD005590PubMed
86.
Colby C et al (1999) A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 24(8):897–902PubMedCrossRef
87.
Link H et al (1993) Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT. Bone Marrow Transplant 11(5):403–406PubMed
88.
Marras TK et al (2002) Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation. Transpl Infect Dis 4(2):66–74PubMedCrossRef
89.
Chan C et al (1999) Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 180(2):369–376PubMedCrossRef
90.
Souza JP et al (1999) High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clin Infect Dis 29(6):1467–1471PubMedCrossRef
91.
Tomonari A et al (2008) No occurrence of Pneumocystis jiroveci (carinii) pneumonia in 120 adults undergoing myeloablative unrelated cord blood transplantation. Transpl Infect Dis 10(5):303–307PubMedCrossRef
92.
Hughes W et al (1993) Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 328(21):1521–1527PubMedCrossRef
93.
El-Sadr WM et al (1998) Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 339(26):1889–1895PubMedCrossRef
94.
Kontoyiannis DP et al (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50(8):1091–1100PubMedCrossRef
95.
Martino R et al (2002) Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 116(2):475–482
96.
Balloy V, Chignard M (2009) The innate immune response to Aspergillus fumigatus. Microbes Infect 11(12):919–927PubMedCrossRef
97.
Zhang P et al (2010) Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: a single-institution experience. Transpl Infect Dis 12(4):316–321PubMedCrossRef
98.
Garcia-Vidal C et al (2008) Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 47(8):1041–1050PubMedPubMedCentralCrossRef
99.
Post MJ et al (2007) Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 9(3):189–195PubMedCrossRef
100.
Lewis RE et al (2013) Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 56(6):638–645PubMedCrossRef
101.
Sinko J et al (2008) Invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients: an autopsy-driven survey. Transpl Infect Dis 10(2):106–109PubMedCrossRef
102.
Chamilos G et al (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 91(7):986–989PubMed
103.
Cordonnier C et al (2006) Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 42(7):955–963PubMedCrossRef
104.
Cordonnier C et al (2010) Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 95(10):1762–1768PubMedPubMedCentralCrossRef
105.
Ostrosky-Zeichner L (2004) Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 23(10):739–744PubMedCrossRef
106.
Paphitou NI, Ostrosky-Zeichner L, Rex JH (2005) Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 43(3):235–243PubMedCrossRef
107.
Wenzel RP, Gennings C (2005) Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 41(Suppl 6):S389–S393PubMedCrossRef
108.
Ruping MJ et al (2010) Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 65(2):296–302PubMedCrossRef
109.
Neofytos D et al (2009) Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 48(3):265–273PubMedCrossRef
110.
Cornely OA et al (2015) Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother 59(4):2078–2085PubMedPubMedCentralCrossRef
111.
112.
Maertens JA et al (2016) Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387(10020):760–769PubMedCrossRef
113.
Mousset S et al (2014) Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 93(1):13–32PubMedCrossRef
114.
Wingard JR et al. (2010) Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allo hematopoietic cell transplantation (HCT). Blood 116(24):5111–5118
115.
Cornely OA et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348–359PubMedCrossRef
116.
Duarte RF et al (2014) Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother 58(10):5758–5765PubMedPubMedCentralCrossRef
117.
Cornely OA et al. (2016) Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother 71(6):1747
118.
van Burik JA et al (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39(10):1407–1416PubMedCrossRef
119.
Marr KA et al (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103(4):1527–1533PubMedCrossRef
120.
Glasmacher A et al (1998) Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 12(9):1338–1343PubMedCrossRef
121.
Glasmacher A et al (1999) Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 42(7–8):443–451PubMedCrossRef
122.
Goodman JL et al (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326(13):845–851PubMedCrossRef
123.
Marr KA et al (2000) Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 96(6):2055–2061PubMed
124.
Slavin MA et al (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis 171(6):1545–1552PubMedCrossRef
125.
Ullmann AJ et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356(4):335–347PubMedCrossRef
126.
Cordonnier C et al (2004) Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 33(9):943–948PubMedCrossRef
127.
de Fabritiis P et al (2007) Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 40(3):245–249PubMedCrossRef
128.
Gupta S et al (2007) Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 9(2):156–160PubMedCrossRef
129.
Wingard JR et al (1999) Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29(6):1402–1407PubMedCrossRef
130.
Bates DW et al (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32(5):686–693PubMedCrossRef
131.
Ullmann AJ et al (2006) Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 43(4):e29–e38
132.
Penack O et al (2006) Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 17(8):1306–1312PubMedCrossRef
133.
Behre GF et al (1995) Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 71(6):287–291PubMedCrossRef
134.
Luu Tran H et al. (2014) Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease. J Oncol Pharm Pract 22(2):228–234
135.
Cornely OA, Ullmann AJ (2011) Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther 89(3):351–352PubMedCrossRef
136.
Kawamura K et al (2014) Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. Int J Infect Dis 19:26–32PubMedCrossRef
137.
Meyers JD, Flournoy N, Thomas ED (1980) Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 142(3):338–346PubMedCrossRef
138.
Saral R et al (1981) Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 305(2):63–67PubMedCrossRef
139.
Gluckman E et al (1983) Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet 2(8352):706–708PubMedCrossRef
140.
Wade JC et al (1982) Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med 96(3):265–269PubMedCrossRef
141.
Wade JC et al (1984) Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 100(6):823–828PubMedCrossRef
142.
Ljungman P et al (1986) Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1(2):185–192PubMed
143.
Sauerbrei A et al (2011) Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2. Antivir Ther 16(8):1297–1308PubMedCrossRef
144.
McLaren C, Sibrack CD, Barry DW (1982) Spectrum of sensitivity of acyclovir of herpes simplex virus clinical isolates. Am J Med 73(1A):376–379PubMedCrossRef
145.
Piret J, Boivin G (2011) Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 55(2):459–472PubMedCrossRef
146.
Mertz GJ et al (1997) Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med 157(3):343–349PubMedCrossRef
147.
Tyring SK, Baker D, Snowden W (2002) Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years’ experience with acyclovir. J Infect Dis 186(Suppl 1):S40–S46PubMedCrossRef
148.
Garner JS (1996) Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hospital Epidemiol 17(1):53–80
149.
Josephson A, Gombert ME (1988) Airborne transmission of nosocomial varicella from localized zoster. J Infect Dis 158(1):238–241PubMedCrossRef
150.
Koc Y et al (2000) Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 6(1):44–49PubMedCrossRef
151.
Rumke HC et al (2011) Immunogenicity and safety of a measles-mumps-rubella-varicella vaccine following a 4-week or a 12-month interval between two doses. Vaccine 29(22):3842–3849PubMedCrossRef
152.
Han CS et al (1994) Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 13(3):277–283PubMed
153.
Locksley RM et al (1985) Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 152(6):1172–1181PubMedCrossRef
154.
Weinstock DM, Boeckh M, Sepkowitz KA (2006) Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 12(10):1096–1097PubMedCrossRef
155.
Zaia JA et al (1983) Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 147(4):737–743PubMedCrossRef
156.
Boeckh M et al (2006) Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood 107(5):1800–1805PubMedPubMedCentralCrossRef
157.
Erard V et al (2007) Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 196(2):266–270PubMedCrossRef
158.
Thomson KJ et al (2005) The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 35(11):1065–1069PubMedCrossRef
159.
Kanda Y et al (2001) Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 28(7):689–692PubMedCrossRef
160.
Gilbert C, Bestman-Smith J, Boivin G (2002) Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 5(2):88–114PubMedCrossRef
161.
Kroger N et al (2001) Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 113(4):1060–1071PubMedCrossRef
162.
Boeckh M, Nichols WG (2004) The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103(6):2003–2008PubMedCrossRef
163.
Thiele T et al (2011) Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 51(12):2620–2626PubMedCrossRef
164.
Narvios AB et al (2005) Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients. Bone Marrow Transplant 36(6):499–501PubMedCrossRef
165.
Kekre N et al (2013) Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction? Biol Blood Marrow Transplant 19(12):1719–1724PubMedCrossRef
166.
Bowden RA et al (1991) Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 78(1):246–250PubMed
167.
Bowden RA et al (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86(9):3598–3603PubMed
168.
Miller WJ et al (1991) Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant 7(3):227–234PubMed
169.
De Witte T et al (1990) Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 50(6):964–968PubMedCrossRef
170.
Narvios AB, Lichtiger B (2001) Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study. Haematologica 86(7):749–752PubMed
171.
Zaia JA et al (1997) Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 176(3):782–785PubMedCrossRef
172.
Nagler A et al (1994) Cytomegalovirus pneumonia prior to engraftment following T-cell depleted bone marrow transplantation. Med Oncol 11(3–4):127–132PubMedCrossRef
173.
Schmidt-Hieber M et al (2010) Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol 91(5):877–885PubMedCrossRef
174.
Einsele H et al (1991) Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet 338(8776):1170–1172PubMedCrossRef
175.
Li CR et al (1994) Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83(7):1971–1979PubMed
176.
O’Brien S et al (2008) Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111(4):1816–1819PubMedCrossRef
177.
Boeckh M et al (2015) Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med 162(1):1–10PubMedPubMedCentralCrossRef
178.
Ruutu T et al (1997) No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. the Nordic BMT Group. Bone Marrow Transplant 19(3):233–236PubMedCrossRef
179.
Zikos P et al (1998) A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT). Haematologica 83(2):132–137PubMed
180.
Meyers JD et al (1988) Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 318(2):70–75PubMedCrossRef
181.
Winston DJ et al (2003) Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis 36(6):749–758PubMedCrossRef
182.
Ljungman P et al (2002) Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 99(8):3050–3056PubMedCrossRef
183.
Vusirikala M et al (2001) Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis. Bone Marrow Transplant 28(3):265–270PubMedCrossRef
184.
Boeckh M et al (1995) Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 172(4):939–943PubMedCrossRef
185.
Winston DJ et al (2008) Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 111(11):5403–5410PubMedCrossRef
186.
Avery RK et al (2010) Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transplant Infect Dis 12(6):489–496
187.
Marty FM et al (2011) Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 11(4):284–292PubMedCrossRef
188.
Marty FM et al (2013) CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 369(13):1227–1236PubMedCrossRef
189.
Chemaly RF et al (2014) Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 370(19):1781–1789PubMedCrossRef
190.
Kharfan-Dabaja MA et al (2012) A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12(4):290–299PubMedCrossRef
191.
Curtis RE et al (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94(7):2208–2216PubMed
192.
Bertz H et al (2009) A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoetic cell transplantation: the feasibility of deescalation. Biol Blood Marrow Transplant 15(12):1563–1570PubMedCrossRef
193.
Oertel SH, Riess H (2002) Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations. Recent Results Cancer Res 159:89–95PubMedCrossRef
194.
Davis CL et al (1995) Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant 9(1):53–59PubMed
195.
Liu Q et al (2013) Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. Am J Hematol 88(7):550–555PubMedCrossRef
196.
Meerbach A et al (2008) Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol 80(3):441–454PubMedCrossRef
197.
Gruhn B et al (2003) Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 31(11):1023–1025PubMedCrossRef
198.
Rooney CM et al (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92(5):1549–1555PubMed
199.
Gerdemann U et al (2012) Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 20(8):1622–1632PubMedPubMedCentralCrossRef
200.
Yan J et al (2013) Meta-analysis of prevention and treatment of toxoplasmic encephalitis in HIV-infected patients. Acta Trop 127(3):236–244PubMedCrossRef
201.
Ruskin J, LaRiviere M (1991) Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet 337(8739):468–471PubMedCrossRef
202.
Bretagne S et al (2000) Prospective study of toxoplasma reactivation by polymerase chain reaction in allogeneic stem-cell transplant recipients. Transpl Infect Dis 2(3):127–132PubMedCrossRef
203.
Costa JM et al (2001) Quality control for the diagnosis of Toxoplasma gondii reactivation in SCT patients using PCR assays. Bone Marrow Transplant 28(5):527–528PubMedCrossRef
204.
Katlama C et al (1996) Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 22(2):268–275
205.
Podzamczer D et al (1995) Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group. Ann Intern Med 123(3):175–180PubMedCrossRef
206.
Katlama C et al (1996) Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expand Access Group AIDS 10(10):1107–1112
207.
Garcia Garrido HM et al. (2015) Response to hepatitis A vaccination in immunocompromised travelers. J Infect Dis 212(3):378–385
208.
Yeo W et al (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62(3):299–307PubMedCrossRef
209.
Moses SE et al (2006) Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol 78(12):1560–1563PubMedCrossRef
210.
Locasciulli A et al (2003) Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 31(4):295–300PubMedCrossRef
211.
Knoll A et al (2007) Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 14(7):478–483PubMedCrossRef
212.
Mahale P, Okhuysen PC, Torres HA (2014) Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals? Clin Gastroenterol Hepatol 12(6):1051–1054, e1PubMedCrossRef
213.
Liang TJ, Ghany MG (2014) Therapy of hepatitis C—back to the future. N Engl J Med 370(21):2043–2047PubMedCrossRef
214.
(2013) A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24–28, 2013 * Amsterdam, The NetherlandsSpecial Reporting on:* Simeprevir Plus Peginterferon/Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection* Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naive Patients* Sofosbuvir Plus Ribavirin Demonstrates Significant Efficacy in Multiple HCV Genotype 2/3 Populations* Daclatasvir Plus Sofosbuvir with or without Ribavirin Yields 100% SVR24 Rate in Genotype 1 Patients Who Fail Telaprevir or Boceprevir* Addition of TG4040 Vaccine to Peginterferon/Ribavirin Increases Sustained Virologic Response Rate at 24 Weeks in Genotype 1 Hepatitis C InfectionPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDJoan Sanford I. Weill Medical College at Cornell UniversityNew York, New York. Gastroenterol Hepatol (N Y) 9(6 Suppl 3): 1–18
215.
Raboni SM et al (2003) Respiratory tract viral infections in bone marrow transplant patients. Transplantation 76(1):142–146PubMedCrossRef
216.
Roghmann M et al (2003) Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant 32(11):1085–1088PubMedCrossRef
217.
Sullivan KM et al. (2001) Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematol Am Soc Hematol Educ Program 392–421
218.
Lehners N et al (2013) Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit. Bone Marrow Transplant 48(12):1548–1553PubMedCrossRef
219.
Ariza-Heredia EJ et al (2015) Influenza vaccination in patients with cancer: factors associated with vaccination practices for patients and their household members. Infect Control Hosp Epidemiol 36(10):1239–1241PubMedCrossRef
220.
Dykewicz CA (2001) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. Biol Blood Marrow Transplant 7(Suppl):19S–22S
221.
Cortez K et al (2002) Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation. J Infect Dis 186(6):834–838PubMedCrossRef
222.
Robinson P et al (2007) Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev 21(2 Suppl 1):S3–S8PubMedCrossRef
223.
Sullivan KM et al (1990) Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323(11):705–712PubMedCrossRef
224.
Winston DJ et al (1987) Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 106(1):12–18PubMedCrossRef
225.
Raanani P et al (2009) Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol : Off J Am Soc Clin Oncol 27(5):770–781CrossRef
226.
Raanani P et al (2008) Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev 4:CD006501PubMed
227.
Cordonnier C et al (2003) Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 139(1):8–18PubMedCrossRef
228.
Schmidt-Hieber M et al (2009) Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCT. Bone Marrow Transplant 44(3):185–192PubMedCrossRef
229.
Norlin AC et al (2008) Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant 41(3):267–273PubMedCrossRef
230.
Sneller MC et al (1993) NIH conference. New insights into common variable immunodeficiency. Ann Intern Med 118(9):720–730PubMedCrossRef
231.
Kerr JP et al (2003) The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol 123(1):114–118PubMedCrossRef
232.
Oza A et al (2006) Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage. Transfusion 46(1):14–23PubMedCrossRef
233.
EMA (2006) E.M.A., Guideline on clinical evaluation of new vaccines. EMEA/CHMP/VWP/164653/2005
234.
Dignani MC et al (2002) Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation. Bone Marrow Transplant 29(3):263–267PubMedCrossRef
235.
Kim DH et al (2008) Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation. Clin Transplant 22(6):770–779PubMedCrossRef
236.
Erard V et al (2007) One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 110(8):3071–3077PubMedCrossRef
237.
Oshima K, et al. (2010) One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Transpl Infect Dis 12(5):421-427
238.
Asano-Mori Y et al (2008) Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 83(6):472–476PubMedCrossRef
239.
Einsele H et al (1995) Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86(7):2815–2820PubMed
240.
Reusser P et al (2002) Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99(4):1159–1164PubMedCrossRef
241.
Einsele H et al (2006) Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 107(7):3002–3008PubMedCrossRef
242.
Ayala E et al (2006) Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 37(9):851–856PubMedCrossRef
243.
Burns LJ et al (2002) Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant 30(12):945–951PubMedCrossRef
244.
Verdonck LF et al (1997) A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin Infect Dis 24(5):901–907PubMedCrossRef
245.
Micklethwaite K et al (2007) Ex vivo expansion and prophylactic infusion of CMV-pp 65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 13(6):707–714PubMedCrossRef
246.
Lau GK et al (2002) Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 36(3):702–709PubMedCrossRef
247.
Loomba R et al (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148(7):519–528PubMedPubMedCentralCrossRef
248.
Chang TT et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354(10):1001–1010PubMedCrossRef
249.
Tamori A et al (2014) Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy. J Gastroenterol Hepatol 29(9):1715–1721PubMedCrossRef
250.
Shang J et al (2016) A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience. Bone Marrow Transplant 51(4):581–586PubMedCrossRef
251.
Koskinas JS et al (2014) The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. a real life experience from a tertiary center. Eur J Intern Med 25(8):768–771PubMedCrossRef
252.
Leong J et al (2014) Lamivudine resistance leading to de novo hepatitis B infection in recipients of hepatitis B core antibody positive liver allografts. Hepatol Res 44(12):1248–1252PubMedCrossRef
253.
Chiba T et al (2003) Successful clearance of hepatitis B virus after allogeneic stem cell transplantation: beneficial combination of adoptive immunity transfer and lamivudine. Eur J Haematol 71(3):220–223PubMedCrossRef
254.
Matsue K et al (2009) High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients. Eur J Haematol 83(4):357–364PubMedCrossRef
255.
Foppa CU et al (1991) A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine. Eur J Clin Microbiol Infect Dis 10(3):187–189PubMedCrossRef
256.
Katlama C (1991) Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS. Eur J Clin Microbiol Infect Dis 10(3):189–191PubMedCrossRef
257.
Leport C et al (1989) An open study of the pyrimethamine-clindamycin combination in AIDS patients with brain toxoplasmosis. J Infect Dis 160(3):557–558PubMedCrossRef
258.
Cordonnier C et al (2009) Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis 48(10):1392–1401PubMedCrossRef
259.
Seggewiss R, Einsele H (2010) Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 115(19):3861–3868PubMedCrossRef
260.
Eisenberg RA et al (2013) Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 33(2):388–396PubMedCrossRef
261.
Bedognetti D et al (2011) Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximab-containing regimens. J Immunol 186(10):6044–6055PubMedPubMedCentralCrossRef
262.
Berglund A et al (2014) The response to vaccination against influenza A (H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncol 53(9):1212–1220PubMedCrossRef
263.
Juergens C et al. (2014) Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: A randomized open-label trial. Hum Vaccin Immunother 10(5)
264.
Hata A et al (2002) Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 347(1):26–34PubMedCrossRef
265.
Burrows SR et al (1997) Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol 27(7):1726–1736PubMedCrossRef
266.
Dhedin N et al (2014) Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients. Vaccine 32(5):585–591PubMedCrossRef
267.
Olkinuora H et al (2012) Immunity after (re) vaccination of paediatric patients following haematopoietic stem cell transplantation. Acta Paediatr 101(8):e373–e377PubMedCrossRef
268.
Hilgendorf I et al (2011) Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD. Vaccine 29(16):2825–2833PubMedCrossRef
269.
Pao M et al (2008) Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 14(9):1022–1030PubMedPubMedCentralCrossRef
270.
Cordonnier C et al (2010) Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine 28(15):2730–2734PubMedCrossRef
271.
Avetisyan G et al (2008) Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 86(2):257–263PubMedCrossRef
272.
Ljungman P, Avetisyan G (2008) Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant 42(10):637–641PubMedCrossRef
273.
Engelhard D et al (1993) Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant 11(1):1–5PubMed
274.
Gueller S et al (2011) Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 17(10):1546–1550PubMedCrossRef
275.
de Lavallade H et al (2011) Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 96(2):307–314PubMedCrossRef
276.
Inaba H et al (2012) Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. Br J Haematol 156(1):109–117PubMedCrossRef
277.
278.
Edwards KM, Berbers GA (2014) Immune responses to pertussis vaccines and disease. J Infect Dis 209(Suppl 1):S10–S15PubMedCrossRef
279.
Parkkali T et al (1997) A randomized comparison between early and late vaccination with tetanus toxoid vaccine after allogeneic BMT. Bone Marrow Transplant 19(9):933–938PubMedCrossRef
280.
Ljungman P et al (1990) Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 162(2):496–500PubMedCrossRef
281.
Li Volti S et al (1994) Immune status and immune response to diphtheria-tetanus and polio vaccines in allogeneic bone marrow-transplanted thalassemic patients. Bone Marrow Transplant 14(2):225–227PubMed
282.
Dengler TJ et al (1999) Vaccination against tick-borne encephalitis under therapeutic immunosuppression. Reduced efficacy in heart transplant recipients. Vaccine 17(7–8):867–874PubMedCrossRef
283.
Ljungman P, Duraj V, Magnius L (1991) Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 7(2):89–93PubMed
284.
Parkkali T et al (1996) Loss of protective immunity to polio, diphtheria and Haemophilus influenzae type b after allogeneic bone marrow transplantation. APMIS 104(5):383–388PubMedCrossRef
285.
Engelhard D et al (1991) Immune response to polio vaccination in bone marrow transplant recipients. Bone Marrow Transplant 8(4):295–300PubMed
286.
Parkkali T et al (1997) Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT. Bone Marrow Transplant 20(8):663–668PubMedCrossRef
287.
Ljungman P et al (2004) Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients. Bone Marrow Transplant 34(12):1067–1069PubMedCrossRef
288.
Parkkali T et al (2007) A randomized study on donor immunization with tetanus-diphtheria, Haemophilus influenzae type b and inactivated poliovirus vaccines to improve the recipient responses to the same vaccines after allogeneic bone marrow transplantation. Bone Marrow Transplant 39(3):179–188PubMedCrossRef
289.
Barra A et al (1992) Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 166(5):1021–1028PubMedCrossRef
290.
Guinan EC et al (1994) Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 57(5):677–684PubMedCrossRef
291.
Parkkali T et al (1996) A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT. Bone Marrow Transplant 18(5):961–967PubMed
292.
Vance E et al (1998) Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant 22(8):735–741PubMedCrossRef
293.
van Wessel K et al (2011) Nontypeable Haemophilus influenzae invasive disease in The Netherlands: a retrospective surveillance study 2001–2008. Clin Infect Dis 53(1):e1–e7PubMedCrossRef
294.
Kalies H et al (2009) Invasive Haemophilus influenzae infections in Germany: impact of non-type b serotypes in the post-vaccine era. BMC Infect Dis 9:45PubMedPubMedCentralCrossRef
295.
Patel SR et al (2007) Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. Clin Infect Dis 44(5):625–634PubMedCrossRef
296.
Jacobsson S et al (2008) Characteristics of Neisseria meningitidis isolates causing fatal disease. Scand J Infect Dis 40(9):734–744PubMedCrossRef
297.
Poolman JT et al (1986) Meningococcal serotypes and serogroup B disease in north-west Europe. Lancet 2(8506):555–558PubMedCrossRef
298.
Onozawa M et al (2008) HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 14(11):1226–1230PubMedCrossRef
299.
Jaffe D et al (2006) Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood 108(7):2470–2475PubMedPubMedCentralCrossRef
300.
Idilman R et al (2003) Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation. Clin Transplant 17(5):438–443PubMedCrossRef
301.
Ljungman P et al (1989) Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 159(4):610–615PubMedCrossRef
302.
Spoulou V et al (2004) Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants. Bone Marrow Transplant 33(12):1187–1190PubMedCrossRef
303.
King SM et al (1996) Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 17(4):633–636PubMed
304.
Sauerbrei A et al (1997) Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 20(5):381–383PubMedCrossRef
305.
Issa NC et al (2014) Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 20(2):285–287PubMedCrossRef
306.
Kussmaul SC et al (2010) Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant 45(11):1602–1606PubMedCrossRef
307.
Aoki T et al (2016) Safety of live attenuated high-titer varicella-zoster virus vaccine in pediatric allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 22(4):771–775PubMedCrossRef
308.
Cordonnier C et al (2015) Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged >/=2 years: an open-label study. Clin Infect Dis 61(3):313–323PubMedPubMedCentralCrossRef
309.
Begue PC et al (1998) Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents. Pediatr Infect Dis J 17(9):804–809PubMedCrossRef
310.
Meerveld-Eggink A et al (2009) Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 15(12):1523–1530PubMedCrossRef
311.
Townsend K et al. (2014) Evaluation and validation of a serum bactericidal antibody assay for Haemophilus influenzae type b and the threshold of protection. Vaccine 32(43):5650–5656
312.
Pinson JB, Weart CW (1992) New considerations for Haemophilus influenzae type b vaccination. Clin Pharm 11(4):332–336PubMed
313.
Centers for Disease, C. and Prevention (2011) Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease--Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 60(30):1018–1019
314.
Toneatto D et al (2011) Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccin 7(7):781–791PubMedCrossRef
315.
Mahler MB et al (2012) Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18(1):145–149PubMedCrossRef
316.
Beran J, Xie F, Zent O (2014) Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety. Vaccine 32(34):4275–4280PubMedCrossRef
317.
McMahon BJ et al (2009) Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 200(9):1390–1396PubMedCrossRef
318.
Tung J et al (2010) A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. Am J Kidney Dis 56(4):713–719PubMedCrossRef
319.
Kim HN et al (2009) Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 20(9):595–600PubMedCrossRef
320.
Li Volti S et al (1997) Immune status and the immune response to hepatitis B virus vaccine in thalassemic patients after allogeneic bone marrow transplantation. Bone Marrow Transplant 19(2):157–160PubMedCrossRef
321.
Fahlgren K (1988) Two doses of MMR vaccine--sufficient to eradicate measles, mumps and rubella? Scand J Soc Med 16(3):129–135PubMed
322.
American Academy of Pediatrics Committee on Infectious Diseases (1997) Immunization of adolescents: recommendations of the advisory committee on immunization practices, the american academy of pediatrics, the american academy of family physicians, and the american medical association. Pediatrics 99(3):479–488CrossRef
323.
Nader S et al (1995) Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 171(1):13–17PubMedCrossRef
Metadata
Title
Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016
Authors
Andrew J. Ullmann
Martin Schmidt-Hieber
Hartmut Bertz
Werner J. Heinz
Michael Kiehl
William Krüger
Sabine Mousset
Stefan Neuburger
Silke Neumann
Olaf Penack
Gerda Silling
Jörg Janne Vehreschild
Hermann Einsele
Georg Maschmeyer
on behalf of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation)
Publication date
01-09-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2711-1

Other articles of this Issue 9/2016

Annals of Hematology 9/2016 Go to the issue

Letter to the Editor

Congenital dyserythropoietic anemia associated to a GATA1 mutation aggravated by pyruvate kinase deficiency

Review Article

Venous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysis

Letter to the Editor

Rhodotorula mucilaginosa as a cause of recurrent pulmonary infection and liver infiltration in a patient with CLL

Original Article

Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis

Original Article

Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children

Letter to the Editor

An unusual association of paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome, and diffuse large B-cell non-Hodgkin lymphoma in a Caucasian man

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits